Your SlideShare is downloading. ×
First Previous Next Last    Index   Text                 Slide 1 of 17
First Previous Next Last    Index   Text                 Slide 2 of 17
First Previous Next Last    Index   Text                Slide 17 of 17
Effects of Drug-Induced Liver Injury on Hepatology and the                    Practice of Medicine                        ...
PPT SlideDILI Study (phase 2)SummarySummary II
Effects of Drug-Induced Liver Injury on Hepatology and thePractice of Medicine    William M. Lee, MD    Department of Inte...
First Previous Next Last    Index   Text                 Slide 3 of 17
Impact of Drug-Induced Liver Injury on the Public     ●   Rare reactions but severe, often fatal     ●   Little data avail...
First Previous Next Last    Index   Text                Slide 16 of 17
Summary II         Education of physicians is vital     ●   CME offerings     ●   Availability of information: Epocrates, ...
First Previous Next Last    Index   Text                 Slide 4 of 17
First Previous Next Last    Index   Text                 Slide 5 of 17
First Previous Next Last    Index   Text                 Slide 6 of 17
First Previous Next Last    Index   Text                 Slide 7 of 17
First Previous Next Last    Index   Text                 Slide 8 of 17
First Previous Next Last    Index   Text                 Slide 9 of 17
First Previous Next Last    Index   Text                Slide 10 of 17
First Previous Next Last    Index Text                Slide 11 of 17
First Previous Next Last    Index Text                Slide 12 of 17
First Previous Next Last    Index   Text                Slide 13 of 17
First Previous Next Last    Index   Text                Slide 14 of 17
First Previous Next Last    Index Text                Slide 15 of 17
Where Drugs Fit In         Main thrust of current medical care is prescribing     ●   200 billion dollar industry annually...
Summary         Physicians share responsibility with pharmaceutical companies and FDA for         drug reactions     ●   C...
The Liver Works Very Well Too Well?     ●   We trust the liver implicitly     ●   Metabolizes many drugs simultaneously   ...
Why Is Rarity a Problem? Hard to study/hard to define     ●   Cannot plan for it     ●   Cannot recognize it when it comes...
Is anything wrong with approval process?     ●   FDA under pressure to approve drugs     ●   Approval process has been und...
The Doctor’s Dilemma         “First, do no harm”     ●   Be very cautious and not use new drugs     ●   Be more bold and t...
Physician’s Information Sources     ●   Medical school/residency teaching     ●   Practice experience     ●   PDR     ●   ...
What Clinicians Face         Loss of independence/time & financial pressure     ●   Much pressure to prescribe new drugs  ...
PPT Slide         Why post-marketing surveillance fails     ●   Failure to recognize ‘hepatitis’ as drug-induced     ●   I...
Possible solutions         Do we need legislation to make it happen?     ●   More stringent drug testing before release   ...
Ways of improving surveillance     ●   Monitor actively at academic medical centers     ●   Monitor through HMO databases ...
DILI Study (pilot phase)         Retrospective analysis of 300 cases of severe liver injury (SLI) at 6 academic         ce...
PPT Slide       Severe Liver Injury Cases       DILI study; n = 230Previous slide      Next slide     Back to first slide ...
DILI Study (phase 2)         Prospective analysis of severe liver injury at a larger number of academic         centers   ...
Upcoming SlideShare
Loading in...5
×

Effects of Drug-Induced Liver Injury on Hepatology and the ...

281

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
281
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
15
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Effects of Drug-Induced Liver Injury on Hepatology and the ..."

  1. 1. First Previous Next Last Index Text Slide 1 of 17
  2. 2. First Previous Next Last Index Text Slide 2 of 17
  3. 3. First Previous Next Last Index Text Slide 17 of 17
  4. 4. Effects of Drug-Induced Liver Injury on Hepatology and the Practice of Medicine 3/28/01 Click here to start Table of Contents Author: William M. Lee, MD Effects of Drug-Induced Liver Injury on Hepatology and the Practice of Medicine Impact of Drug-Induced Liver Injury on the Public Where Drugs Fit In The Liver Works Very Well Too Well? Why Is Rarity a Problem? Hard to study/hard to define Is anything wrong with approval process? The Doctor’s Dilemma Physician’s Information Sources What Clinicians Face PPT Slide Possible solutions Ways of improving surveillance DILI Study (pilot phase)
  5. 5. PPT SlideDILI Study (phase 2)SummarySummary II
  6. 6. Effects of Drug-Induced Liver Injury on Hepatology and thePractice of Medicine William M. Lee, MD Department of Internal Medicine University of Texas Southwestern Medical Center at Dallas Next slide Back to first slide View graphic version
  7. 7. First Previous Next Last Index Text Slide 3 of 17
  8. 8. Impact of Drug-Induced Liver Injury on the Public ● Rare reactions but severe, often fatal ● Little data available re: true incidence ● Who is to blame? ● What do clinicians want? ● What does the public deserve?Previous slide Next slide Back to first slide View graphic version
  9. 9. First Previous Next Last Index Text Slide 16 of 17
  10. 10. Summary II Education of physicians is vital ● CME offerings ● Availability of information: Epocrates, Medline ● Other uses of technology possible ● Allows physicians to get back to “Do no harm” ● ● ●Previous slide Back to first slide View graphic version
  11. 11. First Previous Next Last Index Text Slide 4 of 17
  12. 12. First Previous Next Last Index Text Slide 5 of 17
  13. 13. First Previous Next Last Index Text Slide 6 of 17
  14. 14. First Previous Next Last Index Text Slide 7 of 17
  15. 15. First Previous Next Last Index Text Slide 8 of 17
  16. 16. First Previous Next Last Index Text Slide 9 of 17
  17. 17. First Previous Next Last Index Text Slide 10 of 17
  18. 18. First Previous Next Last Index Text Slide 11 of 17
  19. 19. First Previous Next Last Index Text Slide 12 of 17
  20. 20. First Previous Next Last Index Text Slide 13 of 17
  21. 21. First Previous Next Last Index Text Slide 14 of 17
  22. 22. First Previous Next Last Index Text Slide 15 of 17
  23. 23. Where Drugs Fit In Main thrust of current medical care is prescribing ● 200 billion dollar industry annually ● Pharmacotherapy impacts lives incrementally ● Rare reactions impact lives more dramaticallyPrevious slide Next slide Back to first slide View graphic version
  24. 24. Summary Physicians share responsibility with pharmaceutical companies and FDA for drug reactions ● Clinicians want no trouble (do no harm to themselves) ● But they don’t help by providing the information they themselves need (case reports the exception) ● Improved surveillance will not come from physicians ● Academic physicians have the intrinsic motivation ● Nationwide surveillance system should be consideredPrevious slide Next slide Back to first slide View graphic version
  25. 25. The Liver Works Very Well Too Well? ● We trust the liver implicitly ● Metabolizes many drugs simultaneously ● So we are doubly surprised when it acts up! ● The rarity of drug reactions and their severity is the problem ● Physicians trust the liver as patients doPrevious slide Next slide Back to first slide View graphic version
  26. 26. Why Is Rarity a Problem? Hard to study/hard to define ● Cannot plan for it ● Cannot recognize it when it comes ● It is catastrophic, like an aneurysm ● Compares to other natural disasters ● But drug-reactions are iatrogenic!Previous slide Next slide Back to first slide View graphic version
  27. 27. Is anything wrong with approval process? ● FDA under pressure to approve drugs ● Approval process has been under attack (7 drugs withdrawn since ‘93) ● Patients apply pressure (for approval) as well ● FDA must serve as gatekeeper/wise fatherPrevious slide Next slide Back to first slide View graphic version
  28. 28. The Doctor’s Dilemma “First, do no harm” ● Be very cautious and not use new drugs ● Be more bold and try new agents without waiting ● Read as much as you can, the data is still not there!Previous slide Next slide Back to first slide View graphic version
  29. 29. Physician’s Information Sources ● Medical school/residency teaching ● Practice experience ● PDR ● Drug Ads/Reps ● Reading the literature--case reports! ● News mediaPrevious slide Next slide Back to first slide View graphic version
  30. 30. What Clinicians Face Loss of independence/time & financial pressure ● Much pressure to prescribe new drugs ● No physician can keep up with all rare reactions/interactions (PDR is hard to read) ● Current surveillance system is inadequate ● But physicians rarely contribute to MedWatch!Previous slide Next slide Back to first slide View graphic version
  31. 31. PPT Slide Why post-marketing surveillance fails ● Failure to recognize ‘hepatitis’ as drug-induced ● If drug is stopped, why report? ● Concern about malpractice/adverse outcome ● Withdrawal with increase ALT’s=assumed trivial ● Meant to, just ran out of time/energy/forgot ● Inadequate clinical information/timing/ concomitant drug use/exclusion of other etiologiesPrevious slide Next slide Back to first slide View graphic version
  32. 32. Possible solutions Do we need legislation to make it happen? ● More stringent drug testing before release ● Active post-marketing surveillance ● Post-marketing studies ? ● More readily accessible drug information ● Better physician post-graduate educationPrevious slide Next slide Back to first slide View graphic version
  33. 33. Ways of improving surveillance ● Monitor actively at academic medical centers ● Monitor through HMO databases ● Continue passive system with incentives ● Revise notification (black box) system ● Technology should help (e.g., Epocrates)Previous slide Next slide Back to first slide View graphic version
  34. 34. DILI Study (pilot phase) Retrospective analysis of 300 cases of severe liver injury (SLI) at 6 academic centers ● Cases accrued through medical records analysis/coding/abnormal lab values ● Case report forms developed ● Criteria for SLI (Bili > 10, INR > 1.5) less strict than for acute liver failure ● Case control format vs. panel of expertsPrevious slide Next slide Back to first slide View graphic version
  35. 35. PPT Slide Severe Liver Injury Cases DILI study; n = 230Previous slide Next slide Back to first slide View graphic version
  36. 36. DILI Study (phase 2) Prospective analysis of severe liver injury at a larger number of academic centers ● Provide data on all forms of hepatitis ● Attribution an issue: causality assessment methods are not foolproof ● Would serve as an early warning system ● Limitation: academic centers onlyPrevious slide Next slide Back to first slide View graphic version

×